iShares Biotechnology ETF (NASDAQ:IBB) Declares Quarterly Dividend of $0.12

iShares Biotechnology ETF (NASDAQ:IBB) declared a quarterly dividend on Monday, March 16th, NASDAQ Dividends reports. Investors of record on Tuesday, March 17th will be paid a dividend of 0.1218 per share by the financial services provider on Friday, March 20th. This represents a c) annualized dividend and a dividend yield of 0.3%. The ex-dividend date of this dividend is Tuesday, March 17th.

iShares Biotechnology ETF Price Performance

IBB stock traded up $0.03 during trading on Tuesday, reaching $167.17. The company had a trading volume of 1,570,684 shares, compared to its average volume of 1,897,801. iShares Biotechnology ETF has a 52 week low of $107.43 and a 52 week high of $179.64. The business has a 50 day moving average of $172.68 and a 200 day moving average of $162.92.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Citigroup Inc. lifted its position in iShares Biotechnology ETF by 40.9% during the fourth quarter. Citigroup Inc. now owns 5,242,688 shares of the financial services provider’s stock valued at $884,808,000 after buying an additional 1,521,992 shares during the period. Morgan Stanley grew its holdings in iShares Biotechnology ETF by 2.5% in the fourth quarter. Morgan Stanley now owns 3,204,126 shares of the financial services provider’s stock worth $540,760,000 after purchasing an additional 76,978 shares during the period. BNP Paribas Financial Markets lifted its holdings in shares of iShares Biotechnology ETF by 11.4% during the fourth quarter. BNP Paribas Financial Markets now owns 2,133,461 shares of the financial services provider’s stock valued at $360,064,000 after purchasing an additional 218,066 shares during the last quarter. JPMorgan Chase & Co. boosted its position in shares of iShares Biotechnology ETF by 27.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,060,048 shares of the financial services provider’s stock worth $153,039,000 after purchasing an additional 226,852 shares in the last quarter. Finally, Raymond James Financial Inc. boosted its position in shares of iShares Biotechnology ETF by 286.2% in the 4th quarter. Raymond James Financial Inc. now owns 994,311 shares of the financial services provider’s stock worth $167,810,000 after purchasing an additional 736,881 shares in the last quarter. Hedge funds and other institutional investors own 62.45% of the company’s stock.

iShares Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.